respiratori
syncyti
viru
rsv
common
caus
lower
respiratori
tract
infect
us
children
year
increas
morbid
mortal
report
patient
prematur
infant
infant
cardiac
diseas
sever
immunocompromis
current
therapeut
option
treatment
rsv
limit
ribavirin
andor
intraven
immunoglobulin
ivig
new
antivir
direct
rsv
develop
efficaci
demonstr
sever
human
challeng
studi
increasingli
pediatr
patient
malign
undergo
transplant
manag
outpati
cancer
care
set
characterist
clinic
outcom
rsv
infect
pediatr
immunocompromis
outpati
may
differ
acut
ill
hospit
inpati
object
studi
describ
clinic
present
outcom
rsv
infect
immunocompromis
outpati
pediatr
popul
use
laboratori
record
identifi
patient
birth
year
age
laboratori
confirm
rsv
direct
fluoresc
antibodi
dfa
revers
chain
reaction
viral
cultur
seattl
children
hospit
seattl
wa
usa
rsv
quantit
viral
load
pcr
threshold
cycl
nasal
swab
sampl
compar
standard
curv
gener
amplif
known
number
rna
transcript
pcr
includ
patient
hematolog
malign
solid
organ
transplant
sot
hematopoiet
cell
transplant
hct
outpati
time
diagnosi
sociodemograph
clinic
laboratori
radiolog
data
abstract
electron
medic
chart
use
standard
form
project
ill
episod
defin
presenc
least
one
respiratori
symptom
cough
wheez
increas
work
breath
rhinorrhea
andor
apnea
patient
rsv
detect
laboratori
test
end
ill
episod
defin
minimum
day
follow
symptom
resolut
first
rsv
ill
episod
patient
includ
analysi
hospit
classifi
base
provid
document
reason
hospit
medic
record
potenti
infect
defin
rsv
ill
patient
seen
clinic
two
eight
day
prior
rsv
detect
potenti
clinic
acquir
neutropenia
defin
absolut
neutrophil
count
anc
lymphopenia
defin
absolut
lymphocyt
count
alc
viral
bacteri
coinfect
determin
chart
review
laboratori
result
obtain
within
hour
diagnosi
chest
imag
obtain
within
seven
day
diagnosi
includ
abnorm
chest
imag
defin
radiolog
result
consolid
alveolar
infiltr
airspac
opac
mortal
defin
death
due
respiratori
failur
data
analyz
use
stata
stata
corp
colleg
station
tx
usa
fisher
exact
test
use
comparison
categor
variabl
wilcoxon
rank
sum
anova
test
use
comparison
continu
variabl
studi
approv
institut
review
board
seattl
children
hospit
ten
patient
chest
imag
perform
abnorm
note
alveolar
infiltr
n
common
find
three
patient
requir
supplement
oxygen
therapi
patient
requir
mechan
ventil
eleven
patient
receiv
antibiot
therapi
indic
includ
febril
neutropenia
bacteremia
pneumonia
minor
patient
n
receiv
ribavirin
andor
ivig
median
day
rang
day
start
day
rang
day
rsv
detect
indic
treatment
ribavirin
ivig
includ
lymphopenia
delay
intensif
phase
chemotherapi
neutropenia
hypogammaglobulinemia
prepar
transplant
one
patient
admit
icu
patient
die
due
rsv
infect
howev
one
patient
infect
rsv
die
due
complic
underli
condit
day
rsv
diagnosi
seven
patient
test
perform
rsv
quantit
viral
load
median
initi
rsv
viral
load
copiesml
rang
patient
sequenti
viral
load
test
figur
patient
femal
hct
recipi
receiv
cours
aerosol
ribavirin
day
rsv
viral
load
measur
rsv
copiesml
patient
b
femal
increas
rsv
viral
load
rsv
copiesml
rsv
copiesml
initi
cours
chemotherapi
second
round
chemotherapi
rsv
viral
load
increas
rsv
copiesml
rsv
copiesml
patient
c
male
hct
recipi
experienc
decreas
viral
load
rsv
copiesml
rsv
copiesml
cours
ribavirin
vast
major
immunocompromis
pediatr
patient
rsv
diagnos
tertiari
care
hospit
period
outpati
follow
diagnos
outpati
specialti
clinic
hospit
follow
detect
rsv
contrast
report
rsv
infect
hospit
immunocompromis
children
patient
less
like
sever
immunocompromis
given
outpati
statu
patient
studi
receiv
ribavirin
andor
ivig
support
care
supplement
oxygen
although
evalu
patient
includ
chest
imag
antibiot
use
overal
impact
rsv
alon
receipt
chemotherapi
immunosuppress
therapi
difficult
assess
group
immunocompromis
children
like
previous
experienc
rsv
infect
immedi
consequ
rsv
infect
gener
sever
child
die
studi
due
caus
studi
previou
studi
report
mortal
rate
rang
patient
chronic
lung
diseas
congenit
heart
diseas
hct
studi
pediatr
immunocompromis
inpati
mortal
report
icu
admiss
rate
believ
low
mortal
popul
due
outpati
popul
well
advanc
support
care
sensit
laboratori
diagnost
techniqu
enabl
time
sensit
detect
rsv
fever
associ
risk
hospit
studi
patient
hematolog
malign
less
like
hospit
colleagu
found
lymphopenia
younger
age
risk
factor
lrti
neither
associ
hospit
compar
studi
also
higher
proport
sot
recipi
may
less
immunocompromis
depend
time
sinc
transplant
degre
immunosuppress
studi
minor
solid
organ
transplant
recipi
studi
hospit
none
die
singl
institut
inpati
studi
report
rsv
commonli
detect
respiratori
viru
particularli
pediatr
lung
transplant
recipi
pediatr
abdomin
transplant
recipi
rsv
infect
report
mortal
rate
howev
studi
primarili
describ
hospit
patient
larger
studi
solid
organ
transplant
recipi
need
address
issu
complet
observ
studi
unabl
determin
treatment
efficaci
ribavirin
ivig
viral
load
observ
viral
load
decreas
initi
ribavirin
treatment
one
patient
increas
sever
round
chemotherapi
one
patient
rsv
immunocompromis
patient
associ
prolong
shed
like
consequ
inabl
host
immun
respons
clear
knowledg
retrospect
prospect
studi
antivir
therapi
rsv
immunocompromis
pediatr
popul
sever
new
rsv
antivir
develop
includ
two
evalu
challeng
studi
healthi
young
adult
assess
sequenti
viral
load
receipt
treatment
assess
correl
clinic
outcom
rel
patient
popul
found
high
rate
rsv
infect
could
potenti
acquir
outpati
clinic
set
rsv
often
implic
inpati
outpati
nosocomi
outbreak
transplant
ward
document
genotyp
although
case
studi
could
link
clinic
visit
children
also
live
home
therefor
like
frequent
contact
individu
interfac
commun
sibl
addit
mani
patient
seen
frequent
least
weekli
per
treatment
protocol
could
also
explain
high
rate
potenti
rsv
infect
limit
studi
includ
use
retrospect
chart
review
singl
institut
possibl
patient
present
care
rsv
infect
omit
studi
howev
immunocompromis
children
receiv
care
institut
also
possibl
miss
case
rsv
due
limit
sensit
dfa
compar
assay
earlier
year
studi
howev
institut
dfa
sensit
compar
young
addit
limit
includ
inabl
discern
true
nosocomi
infect
sequenc
sampl
would
need
perform
identifi
ident
viral
strain
residu
sampl
avail
analysi
conclus
find
signific
burden
rsv
diseas
occur
outpati
immunocompromis
children
low
hospit
rate
mortal
studi
center
studi
therapeut
intervent
trial
new
antivir
consid
inclus
outpati
inpati
immunocompromis
popul
assess
impact
treatment
broadli
repres
patient
popul
hyc
receiv
fund
research
unrel
work
pfizer
glaxo
smith
kline
dmz
receiv
fund
research
unrel
work
chimerix
jae
receiv
reimburs
speak
abbvi
act
paid
consult
gilead
pfizer
inc
jae
institut
receiv
research
support
gilead
pfizer
inc
glaxosmithklin
unrel
work
studi
support
grant
nation
institut
health
usa
hyc
project
redcap
